Articles

PP50 Comparison of xenogeneic graft-versus-host reactions in humanized NSG and NSG-HLA-A2/HHD mice

BJH - volume 8, issue Abstract Book BHS, february 2017

G. Ehx , G. Fransolet , L. Delens , J. Muller MSc, Y. Beguin MD, PhD, S. Humblet-Baron , M. Hannon , F. Baron MD, PhD

Read more

O.5 Sequential administration of 5-azacytidine (AZA) and donor lymphocyte infusion (DLI) for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) in relapse after allogeneic stem cell transplantation (SCT): an interim analysis from the Belgian Hematology Society (BHS)

BJH - volume 8, issue Abstract Book BHS, february 2017

X. Poiré MD, C. Graux MD, PhD, A. Ory , J. Jamart , F. Frédéric , H. Schoemans MD, PhD, P. Lewalle MD, PhD, A. De Becker MD, D. Deeren , Z. Berneman MD, PhD, T. Kerre MD, PhD, P. Zachée MD, PhD, D. Selleslag MD, Y. Beguin MD, PhD

Read more

Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

BJH - volume 7, issue 6, december 2016

S. Servais MD, PhD, C. Grégoire MD, F. Baron MD, PhD, E. Willems MD, PhD, A. Briquet PhD, E. Baudoux MD, O. Delloye PhD, O. Giet PhD, C. Lechanteur PhD, Y. Beguin MD, PhD

Summary

Steroid-refractory acute graft-versus-host disease is a severe complication after allogeneic stem cell transplantation. So far, its treatment remains very challenging since the current therapies do not offer significant benefits. Among the most recent approaches, multipotent mesenchymal stromal cell-based therapy has attracted great interest over the past decade. Here, we briefly reviewed the current knowledges about the immunomodulatory properties of multipotent mesenchymal stromal cells as well as results of preclinical and clinical studies having assessed their efficacy to modulate steroid-refractory acute graft-versus-host disease.

(BELG J HEMATOL 2016;7(6):229–35)

Read more

O.4 SRC kinase inhibition with saracatinib limits the development of osteolytic bone disease in multiple myeloma

BJH - volume 7, issue Abstract Book BHS, january 2016

R. Heusschen PhD, J. Muller MSc, M. Binsfeld , E. Plougonven , N. Mahli , G. Carmeliet , A. Léonard , F. Baron MD, PhD, M. Cohen-Solal , K. Vanderkerken PhD, Y. Beguin MD, PhD, E. Menu , J. Caers MD, PhD

Read more

P2.06 Salt but not glucocorticosteroïds enhances Th17 differentiation from naïve T cells in vitro

BJH - volume 7, issue Abstract Book BHS, january 2016

L. Delens , S. Servais MD, PhD, L. Vrancken , G. Ehx , G. Fransolet , M. Hannon , S. Dubois , C. Daulne , Y. Beguin MD, PhD, F. Baron MD, PhD

Read more

PP4.2 The clinical relevance of imatinib (Im) plasma trough concentration in patients with chronic myelocytic leukemia (CML) in chronic phase. A Belgian retrospective study

BJH - volume 7, issue Abstract Book BHS, january 2016

F. Van Obbergh MD, L. Knoops MD, PhD, Y. Beguin MD, PhD, C. Graux MD, PhD, S. Benghiat MD, PhD, K. Kargar-Samani , D. Bauwens , A. Efira MD, C. Dubois , C. Springael MD, PhD, L. Montfort , T. Connerotte , A. Delannoy , P. Wallemacq

Read more

PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice

BJH - volume 7, issue Abstract Book BHS, january 2016

C. Grégoire MD, Y. Beguin MD, PhD, M. Hannon , S. Dubois , B. Baudoux , A. Briquet PhD, C. Lechanteur PhD, G. Ehx , F. Baron MD, PhD

Read more